Biopharma | May 24, 2025
Sun Pharma to raise stake in US-based Pharmazz to 22.7%
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Awards highlight Avantor's commitment to the Biopharma industry
Subscribe To Our Newsletter & Stay Updated
